Pliant Therapeutics Inc
PLRX1.655USD
+0.075+4.75%
交易中 （美東）報價延遲15分鐘
101.59M總市值
虧損本益比TTM
關於 Pliant Therapeutics Inc 公司
Pliant Therapeutics, Inc. 是一家臨牀階段的生物技術公司。該公司專注於發現和開發用於治療纖維化和相關疾病的療法。其主要候選產品 bexotegrast (PLN-74809) 是一種口服小分子 αvß6 和 αvß1 整合素雙重選擇性抑制劑，正在開發用於治療特發性肺纖維化 (IPF) 和原發性硬化性膽管炎 (PSC) 的主要適應症。該公司已啓動 BEACON-IPF，這是一項針對 IPF 的 bexotegrast 的 2b 期試驗。它還開發了 PLN-1474，一種用於治療伴有肝纖維化的非酒精性脂肪性肝炎 (NASH) 的小分子選擇性抑制劑。該公司已啓動第三個臨牀項目 PLN-101095 的 1 期研究，PLN-101095 是一種小分子、αvß8 和 αvß1 整合素的雙選擇性抑制劑，正在開發用於治療實體腫瘤。該公司有一個臨牀前項目 PLN-101325，針對肌肉營養不良症。
公司簡介
公司代碼PLRX
公司名稱Pliant Therapeutics Inc
上市日期Jun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
員工數量171
證券類型Ordinary Share
年結日Jun 03
公司地址331 Oyster Point Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16504816770
網址https://pliantrx.com/
公司代碼PLRX
上市日期Jun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Dr. Delphine Imbert, Ph.D.
Dr. Delphine Imbert, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
持股股東
持股股東
佔比
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
股東類型
持股股東
佔比
Hedge Fund
35.59%
Investment Advisor
28.68%
Investment Advisor/Hedge Fund
19.92%
Research Firm
5.73%
Venture Capital
4.24%
Individual Investor
3.04%
Family Office
0.87%
Bank and Trust
0.30%
Pension Fund
0.22%
Other
1.42%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
370
63.27M
103.07%
-13.14M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
2023Q2
347
62.06M
104.99%
-496.00K
2023Q1
337
60.53M
102.92%
+8.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Tang Capital Management, LLC
6.00M
9.77%
+6.00M
--
Mar 31, 2025
Deep Track Capital LP
5.40M
8.8%
-572.58K
-9.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
7.4%
+52.45K
+1.17%
Mar 31, 2025
The Vanguard Group, Inc.
3.33M
5.42%
+105.82K
+3.29%
Mar 31, 2025
Cormorant Asset Management, LP
3.00M
4.89%
+3.00M
--
Mar 31, 2025
Blue Owl Capital Holdings LP
2.97M
4.84%
+200.00K
+7.22%
Mar 31, 2025
UBS Financial Services, Inc.
2.65M
4.31%
+2.02M
+321.08%
Mar 31, 2025
Woodline Partners LP
2.51M
4.1%
+2.39M
+1875.01%
Mar 31, 2025
Third Rock Ventures, LLC
2.13M
3.47%
--
--
Mar 31, 2025
Redmile Group, LLC
2.05M
3.35%
-841.92K
-29.08%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
查看更多
Vanguard US Value Factor ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
SPDR S&P Pharmaceuticals ETF
佔比0%
Invesco RAFI US 1500 Small-Mid ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
